Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)

Key facts

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Principal Investigator

Nyall R London, MD, Ph.D, MD

Otolaryngology - Broadway

Intervention

Toripalimab + Chemotherapy(drug)

Enrollment

75 target

Eligibility

18 years · All sexes

Timeline

2026 – 2030

Study locations (1)

• Johns Hopkins Hospital East Baltimore, Baltimore, Maryland, United States

Collaborators

Coherus Oncology, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Squamous cell carcinoma of the larynx

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT06915454
  High-Resolution PET-CT Imaging for Surgical Margin Visualization
  Vanderbilt-Ingram Cancer Center
• RECRUITINGPHASE2NCT06831149
  Use of SPY Imaging System to Minimize Fistulas After Hypopharyngeal Reconstruction
  Matthew Spector
• ACTIVE NOT RECRUITINGPHASE1NCT05540899
  Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer
  American College of Radiology
• RECRUITINGPHASE2NCT06039631
  Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer
  Fudan University
• ACTIVE NOT RECRUITINGPHASE2NCT04030455
  Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer
  M.D. Anderson Cancer Center
• RECRUITINGPHASE1NCT03114462
  Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
  M.D. Anderson Cancer Center

See all trials for Squamous cell carcinoma of the larynx →